Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually

Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually

Sep 22, 2020 | News

“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says

Sep 15, 2020 | News

“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.”

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year

Sep 14, 2020 | Press Releases

Report details five instances of product hopping that collectively cost $4.7 billion annually.

  • Analysis (42)
  • Books (3)
  • Commentary (4)
  • Events (16)
  • Interviews (55)
  • News (54)
  • Op-Eds (82)
  • Press Releases (4)
  • Testimony (20)
  • Regulatory Uncertainty for ESOPs
    New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee OwnershipOctober 2, 2023
  • PBMs in US Drug Pricing Debate
    MGA Releases White Paper on Role of PBMs in US Drug Pricing DebateSeptember 26, 2023
  • Unintended Consequences of Limiting PBMsSeptember 26, 2023
  • Importance of Prescription Drug Rebates
    ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the MediaAugust 11, 2023
  • Congress takes on PBMs
    1 big thing: Congress takes on PBMsAugust 9, 2023
  • Here comes Humira competition
    Here comes Humira competition July 20, 2023
  • Humira Competitors Don’t Guarantee
    Humira Competitors Don’t Guarantee Lower Patient Drug CostsJuly 19, 2023
  • The State of Biosimilars
    The State of Biosimilars: What to WatchJuly 18, 2023
  • Importance of Prescription Drug Rebates
    ‘The Price of Business’: Discussing the Latest Inflation ReportJuly 12, 2023
  • Brill discusses adalimumab market
    Alex Brill Interviewed on the Future of the Adalimumab Market June 28, 2023
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact